Fresenius Brings In Transparency Change For Kabi Unit
Business On Track To Meet Or Exceed Its Targets For The Current Financial Year
Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.
You may also be interested in...
Mabxience Sets Out Investment Plans Under Fresenius Ownership
Unveiling plans to install a new bioreactor at its Genhelix site in Spain, mAbxience is bolstering its biosimilars manufacturing capabilities and CDMO capacity under the majority ownership of Fresenius Kabi.
Fresenius Pushes Kabi Even Higher As Former Sandoz Exec Named CEO
The Fresenius group spoke at length about its core Fresenius Kabi business during the company’s year-end financial call, not least its under pressure IV drugs in the US.
Kabi ‘Overdelivering’ On Saving Plans But Feels The Sting Of Inflation
Newly instated Fresenius group CEO Michael Sen took charge of his first earnings call following his appointment on 1 October, pushing the message of Kabi managing its own destiny amid a series of macroeconomic challenges.